Here are 8 promising biotechs priced for a buyout if their products can deliver: BioMarin Pharmaceutical Inc. (

): It's not the most profitable company, but BioMarin Pharmaceuticals certainly has some promising products in its portfolio. The company first achieved profitability in 2008, and its two largest revenue drivers in 2010 were Naglazyme (14% growth to $193 [...]

Go to http://SwingTradingDaily.com for full article, videos and real-time updates.